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Abstract 
 
The extracellular milieu is rich in growth factors that drive tumor progression, 
but the mechanisms that govern tumor cell sensitivity to those ligands have not 
been fully defined. In this study, we address this question in mice that develop 
metastatic lung adenocarcinomas through the suppression of the microRNA-
200 (miR-200) family. Cancer-associated fibroblasts (CAF) enhance tumor 
growth and invasion by secreting VEGF-A that binds to VEGFR1, a process 
required for tumor growth and metastasis in mice and correlated with a poor 
prognosis in lung adenocarcinoma patients.  In this study, we discovered that 
miR-200 blocked CAF-induced tumor cell invasion by directly targeting 
VEGFR1 in tumor cells. In the context of previous studies, our findings suggest 
that the miR-200 family is a point of convergence for diverse biologic processes 
that regulate tumor cell proliferation, invasion, and metastasis; its target genes 
 ix 
drive epithelial-to-mesenchymal transition (ZEB1 and ZEB2) and promote 
sensitivity to a potent tumor growth factor emanating from the microenvironment 
(VEGFR1). Clinical trials should focus not only on the role of VEGFR1 in 
angiogenesis but also on the expression and activation of VEGFR1 in tumor 
cells by stromal sources of VEGF-A in the tumor microenvironment as a target 
for metastasis prevention. 
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Introduction 
 
 
 
 
 
 
 
 
 
 2 
Lung Cancer 
According to the 2008 cancer statistics, cancer is the second leading 
cause of death in the U.S. following heart disease, with little improvement over 
the past thirty years for overall-survival with current modalities for treatment and 
prevention (Jemal et al., 2010a; Jemal et al., 2010b). Cancer arising in the lung 
and bronchus is the second highest in estimated new cases (116,750 male and 
105,770 female) of the ten leading cancer types and the leading cause of 
estimated deaths for 2010 (86,200 male and 71,080 female, Figure 1A)(Jemal 
et al., 2010b). The estimated 2010 statistics clearly demonstrate that the annual 
age-adjusted cancer death rates from 1930 to 2006 have shown little significant 
improvement in the treatment of lung cancer in females, with only a marginal 
improvement in males (Jemal et al., 2010b). At time of diagnosis, patients with 
lung cancer typically present advanced late-stage metastatic disease that is 
inoperable and has the smallest chance of survival out of all the stages 
(localized, regional, and distant, Figure 1B and 1C)(Jemal et al., 2010b). Lung-
cancer diagnosis and treatments have not improved over the past thirty years 
for two reasons: not only do we currently lack tools and animal models that 
represent the metastatic disease seen in advance-staged lung cancer patients, 
but also we need more detailed knowledge of the tumor microenvironment to 
understand the disease and the molecular switches regulated by the different 
components (i.e. different cells, soluble-secreted proteins, extracellular matrix, 
etc.). 
 
A 
B C 
Figure 1:  Lung Cancer Statistics. 
(A) Depicts the ten leading cancer types for the estimated new cases and (B) 
deaths by gender for the year 2010. (C) The stage distribution of selected 
cancers by race at diagnosis within the United States from the year 1999 to 
2005.  (D) The five-year relative survival rates among patients diagnosed with 
selected cancers stage at diagnosis and race within the United States from the 
year 1999 to 2006. 
Adapted from: Jemal 2010. 
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A Model of Advanced Lung Cancer Disease 
Fortunately in more recent years researchers have created a lung cancer 
mouse model that develops advanced lung adenocarcinomas with defined 
metastatic potential, hereafter termed K-ras;p53 mutant mice (Gibbons et al., 
2009a; Roybal et al., 2011). These mice express two specific mutations: a 
common Li-Fraumeni Tp53 mutation (p53R172H) found in Li-Fraumeni patients 
and a K-ras (K-rasG12D) mutation that results in sporadic lung cancers that 
develop metastatic disease. Expression profiling of the tumors from these mice 
has demonstrated an analog between the mice and a subset of NSCLC patients 
with a poor prognosis (Gibbons et al., 2009a).  These genetically engineered 
mouse models are valuable tools that allow researchers to study the genetic 
effects that promote metastatic lung disease and test an array of hypotheses 
that could lead to potential therapeutics for the treatment of the disease. This 
model is very robust not only because of its genetic background but also 
because the mice are immunocompetent, allowing the mice to undergo normal 
immunological responses, which permit researchers to survey the local and 
metastatic tumor microenvironment in vivo. 
 
The Tumor Microenvironment 
Within the tumor microenvironment, a great deal of changes can occur in 
response to various cell types (i.e. fibroblasts, endothelial cells, macrophage, 
etc.), secreted soluble/diffusible factors (cytokines, chemokines, and growth 
factors), and structural extracellular matrix proteins (collagen, elastin, 
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fibronectin, etc.) that can influence the tumor and the surrounding stroma 
(Figure 2). Previous studies have clearly demonstrated that the infiltrating 
activated stromal cells can govern the metastatic potential of cancer cells by 
secreting a number of soluble factors within the microenvironment; these 
soluble factors then bind to cognate receptors on cancer cells causing 
inflammation, cell proliferation, and a number of other tumor-promoting events 
(Roybal et al., 2011).  Despite knowing how secreted soluble factors influence 
other types of cancers the cytokine milieu has not been fully elucidated in 
metastatic NSCLC.    
One of these activated stromal cells, a polarized M2 macrophage, has 
been shown to promote tumor progression (Mantovani et al., 2004; Mantovani 
et al., 2002). The activation of the M2 macrophage from the M1 macrophage, 
which aids in the immune response and is non-tumor promoting, is due in part 
to the cytokine milieu present within the tumor microenvironment.  In addition to 
these macrophages, fibroblasts within the local and tumor microenvironment 
also secrete soluble factors and produce the extracellular matrix that governs 
the niche.  
 
Fibroblasts and Cancer 
A growing body of evidence suggests that metastasis is regulated by 
cells involved in inflammation, angiogenesis, and structural remodeling; 
however, the role of fibroblasts in metastatic NSCLC cancer has not been fully 
elucidated (Shimoda et al.; Wu and Zhou, 2009; Zhou et al., 2006).  
Figure 2:  The Tumor Microenvironment. 
Schematic representation of the biologic activities within the tumor 
microenvironment.  Fibroblasts (highlighted in red boxes), the cell of interest 
in our research goals, are depicted as non-tumorigenic fibroblasts 
(Fibroblasts) that transition to activated fibroblasts, which ultimately lead to 
pro-tumorigenic carcinoma-associated fibroblasts (CAF).  This figure also 
shows VEGF-A and its receptor VEGFR-1 as contributing to the tumor 
microenvironment.  Soluble-secreted factors are capable of eliciting multiple 
effects within the tumor microenvironment; the figure depicts TGF-β causing 
cells to undergo EMT/invasion and proliferation/differentiation of CAF. 
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Central to these processes are cancer-associated fibroblasts (CAF), which were 
initially described as myofibroblasts; however, not all CAF have these features 
(Desmouliere et al., 2004; Sugimoto et al., 2006). CAF have multiple cells-of-
origin, including resident fibroblasts, endothelial cells, adipocytes, and bone 
marrow-derived mesenchymal cells (Wu and Zhou, 2009). CAF play a 
functional role in tumor progression as shown by genetic and pharmacologic 
approaches to eradicate CAF in mice and by studies on human primary tumors 
that have correlated CAF gene expression with a poor prognosis (Chang et al., 
2004; Santos et al., 2009). CAFs promote tumorigenesis by recruiting 
macrophages and suppressing T cell anti-tumor immunity (Erez et al.; Nazareth 
et al., 2007). These cells interact through paracrine mechanisms by secreting 
matrix metalloproteinases and ligands for growth factor receptors, interleukin 
receptors, CC chemokine receptors, CXC chemokine receptors, and other 
factors (Wu and Zhou, 2009; Erez et al.; Anderberg et al., 2009). Although 
many of these proteins bind directly to receptors on tumor cells and may 
thereby control tumor progression, little is known about the mechanisms that 
regulate tumor cell sensitivity to those cytokines.  
 
miR-200 and Metastasis 
Recent studies, ranging in multiple organ types and systems in cancer, 
have provided evidence that miRNA are capable of governing cellular 
processes that promote or aid tumorigenesis and metastases (Gibbons et al., 
2009b).  miRNA are small, single-stranded, non-coding RNA gene products 
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(19-25 nucleotide bases in length) formed from double-stranded RNA (dsRNA) 
that are processed from an immature form to a mature miRNA in order to 
regulate gene expression (Shenouda and Alahari, 2009; Carletti and 
Christenson, 2009).  The mature miRNA binds onto the 3’ untranslated region 
(3’-UTR) on the target messenger RNA (mRNA), thereby regulating gene 
expression either by controlling translational efficiency or by degrading the 
transcript.  More specifically, miR-200 is one family of miRNA that has been 
shown to be regulated by Zeb1 and Zeb2 transcription factors, which decrease 
miR-200 levels, promote metastases, and induce EMT (epithelial to 
mesenchymal transformation) under TGF-β stimulation (Gibbons et al., 2009b; 
Wipff et al., 2007). Additionally low expression levels of miR-200b, one of the 
five miR-200 family members, has been correlated to a specific subset of lung 
adenocarcinoma patients and predicts a high probability of recurrence of 
disease. Although we know that miR-200 is a central regulator of metastasis, 
the current evidence demonstrates a critical need to identify miR-200 target 
genes involved in this process and its role within the tumor microenvironment. 
This study postulates that miR-200 targets cell surface receptors that transmit 
paracrine signals from the microenvironment. A CAF population was isolated 
from lung adenocarcinomas in mice by using antibodies against Thy-1 (CD90), 
a cell surface glycoprotein that is expressed primarily on lung fibroblasts, neural 
cells, and leukocytes (Rege and Hagood, 2006; Hardie et al., 2009). Findings 
from these studies revealed sharp differences between CAF and their normal 
lung tissue counterpart; the CAF had more prominent interactions with tumor 
 9 
cells driven in part by secretion of vascular endothelial growth factor-A (VEGF-
A), which enhanced tumor cell proliferation and invasion.  Tumor cells blocked 
their interactions with CAF through miR-200, which directly targeted 
VEGFR1(Flt1) in tumor cells. These findings demonstrate a novel role for miR-
200 in the regulation of tumor cell sensitivity to a paracrine signal emanating 
from the microenvironment.   
 
Significance 
In the context of what has been reported previously, the findings 
presented here suggest that the microRNA-200 family (miR-200) is a point of 
convergence for diverse biologic processes. The upregulation of its target 
genes ZEB1 and ZEB2 drive epithelial-to-mesenchymal transition (EMT), and 
increased expression of VEGFR1 promotes sensitivity to VEGF-A, all of which 
regulate tumor cell proliferation, invasion, and metastasis. Although its role in 
angiogenesis has been the focus of clinical trials, VEGFR1 expression in tumor 
cells and its activation by cellular sources (i.e. epithelial cells or stromal cells 
such as CAFs) of VEGF-A in the tumor microenvironment are legitimate targets 
for metastasis prevention. 
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Chapter Two 
Materials & Methods 
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Animal Husbandry: Before their initiation, all mouse experiments were 
submitted for approval to the Institutional Animal Care and Use Committee 
(IACUC) at the University of Texas-M.D. Anderson Cancer Center. 129/SV mice 
were fed sterile mouse pellets and acidified water ad libitum. Mice were housed 
in ventilated cages equipped with micro-isolator lids and maintained under strict 
containment protocols. Evidence of bacterial, parasitic, or fungal infection was 
tested, and serology was performed on cage littermates for 12 of the most 
common murine viruses. All mice were euthanized according to the standards 
set forth by the IACUC. 
 
Antibodies and Recombinant Peptides: We purchased Vimentin and a-SMA 
for immunocytochemistry staining of primary cells.  Sheep anti-Rat Magnetic 
Dynabeads beads (Invitrogen) were purchased and conjugated to rat anti-
mouse antibodies: CD68 (Abcam), CD326 (BD Pharmigen), CD90 (BD 
Pharmigen and Abcam), CD31 (BD Pharmigen), and F4/80 (AbD Serotec and 
Abcam) for isolation of the various primary cells from the lungs.  Western blot 
analysis and immunofluoresence experiments were performed using anti-Thy1 
(Abcam), anti-FSP1 (Abcam), anti-VEGFR1 (R & D Systems), and anti-
VEGFR3 (Santa Cruz Biotechnology) antibodies.  For VEGF neutralization and 
treatment studies, the cells were treated with VEGF neutralizing antibodies, 
control IgG, or recombinant murine VEGF (R&D Systems), and Avastin 
(Bevacizumab, Genentech/Roche) provided by M.D. Anderson Cancer Center 
Pharmacy.  For flow cytometry and FACs analysis anti-Thy1-APC (BD 
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Pharmigen), 7AAD Viability Control (Sigma Aldrich), and anti-CD45-APC 
(Abcam) antibodies were purchased for cell surfacing staining and sorting. 
 
Cell Lines:  The culture conditions and derivation of the cell lines used in this 
study (LKR-13, MLg, 344SQ, 393P) have been described previously (Gibbons 
et al., 2009a; Gibbons et al., 2009b; Wislez et al., 2006; Yoshikura and 
Hirokawa, 1974). The Tyler Jacks group gave us the LKR-13 cells 
(Massachusetts Institute of Technology), and we purchased the MLg from 
American Type Culture Collection. 
 
Colony Formation: We formed the cell colonies according to the instructions 
previously published (Roybal et al., 2011; Zhong et al., 2008). Cells (5 x 104 in 
0.3% agar) were seeded onto a layer of 0.8% agar in 6-well plates in normal 
culture medium, allowed to proliferate for 21 days, and stained with 0.5 mg/mL 
nitrotetrazolium blue (Sigma-Aldrich). Colonies were visualized by light 
microscopy (4x) and counted. Results were expressed as the mean ± standard 
deviation and subjected to the Students t-test for statistical significance. 
 
Cytokine Quantification in Conditioned-Medium: We quantified the secreted 
soluble factors in the mono- or co-culture conditioned medmium using 
previously published methods (Roybal et al., 2011). We collected triplicate 
conditioned-medium samples from three independent migration assay 
experiments and subjected the samples (n=9) to Magnetic Bead Luminex Pro 
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Assays according to the manufacturer’s instructions. We calibrated each 
cytokine using a calibration curve ranging from 2.0 to 32,000pg/mL.  We used 
the Bio-Plex 2000 Workstation and Bio-Plex Manager (Version 5) software to 
acquire and analyze the data.  The mean values were calculated from the 
replicates and subjected to the Dunnett’s Statistical Test to determine 
significance between mono-cultures and co-cultures. 
 
FLT1 Transfection shRNA: We performed the FLT1 Transfection shRNA using 
a previously published method (Roybal et al., 2011).  HuSH™ shRNA plasmid 
panels (29-mer) shRNA constructs against Mus Musculus FLT1 in pGFP-V-RS 
Vector (TG514364) and Scramble shRNA as the control were purchased 
(TR30013) in the pGFP-V-RS plasmid (Origene). The following shRNAmir 
sequences were used to create 2 VEGF clones: 5’-
GAAACCACAGCAGGAAGACGGTCCTATCG-3’ and 5’-
TGAAGCGGTTCACCTGGACTGAGACCAAG-3’.   Constructs were cloned into 
competent cells and plated on LB agar containing kanamycin for selection.  We 
removed single colonies from the antibiotic-treated LB agar plates for each 
shRNA construct and scramble control and isolated plasmid DNA for enzyme 
digestion.  After identifying the clones with the shRNA cassette or scramble 
cassette, 344SQ cells were transfected with shRNA or scramble using 
lipofectamine and Opti-MEM for 24 hours in an incubator kept at 37°C at 5% 
CO2.   Transfection media and reagents were washed with PBS 24 hours after 
transfection and replaced with selection media, puromycin (Invitrogen) in 
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RPMI1640 10%FBS (15µg/mL), for selecting clones.  Cells were selected for 
two weeks to generate stable shRNA populations.  Each of the individual clones 
were chosen from the population of selected cells, tested, and used for various 
experiments. 
 
Flow Cytometry: We performed flow cytometry using a procedure similar to 
that in a previously published work (McQualter et al., 2009). Briefly, 129/SV 
mice were sacrificed according to the regulations set forth by IACUC and UT 
M.D. Anderson using CO2 and cervical dislocation.  We isolated the lungs from 
the mice after an intra-tracheal perfusion of HBSS containing 10% FBS (HBSS-
10%).  To dissociate the lungs into a single cell suspension, we used both an 
enzymatic digestion with 3mg/mL Collagenase and 4mg/mL Dispase (Roche) 
and also a lung-specific mechanical technique, the gentleMacs Dissociator 
(Miltenyi Biotec) programs Lung_0.1 and Lung_0.2. The cell suspension was 
placed into a red blood cell lysis buffer (Bio Legend), neutralized and 
centrifuged, resuspended in HBSS-10%, and passed through 70 and 40 micron 
filters to generate a single cell suspension.  Cells were stained with 7AAD, anti-
Thy1-APC, and anti-CD45-APC antibodies for one hour, centrifuged, washed, 
centrifuged, resuspended in 1mL of flow buffer (PBS containing 2% FBS), and 
counted. Flow cytometric analysis was performed using a fluorescence-
activated cell-sorter (FACSDiVA; BD Biosciences), and we analyzed the data 
collected with FlowJo Software. 
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Invasion Assay: We performed an invasion assay using a previously published 
method (Roybal et al., 2011; Zhong et al., 2008). Growth Factor Reduced 
Matrigel Invasion chambers (BD BioCoat™) was purchased.  The upper 
chamber of the 24-well transwell invasion plate was rehydrated with 500 ul of 
warm serum-free containing medium and placed at 37°C at 5% CO2 for two 
hours.  After rehydration, the serum-free containing medium was removed from 
the upper chambers, and the cells were trypsinized, neutralized with their 
normal medium containing 10% FBS, spun down, resuspended in serum-free 
media, counted using a hemocytometer, and placed in the upper chamber at a 
seeding density of 5 X 104 cells per well. The upper chamber containing cells 
was placed into the lower chamber containing media with 2% FBS at a volume 
of 600ul/well to act as a chemoattractant.  Cells were allowed to invade through 
the chamber for 14 hours at 37°C at 5% CO2.  The cells on the upper chamber 
were fixed with 90% ethanol, stained with 0.1% crystal violet blue solution, and 
rinsed in de-ionized water. The inner portion of the top chamber was swabbed 
to remove all the non-invaded cells.  Migrated cells were counted in five 
microscopic fields at 4x magnification, which was represented as the mean ± 
standard deviation and subjected to Students t-test for statistical significance. 
 
Lethal Irradiation and Bone Marrow Engraftment: Total-body irradiation (TBI) 
was performed with a 137Cs irradiator (Mark I-30; GE), and a single dose of 
1000R was given to the recipient animals.  Bone Marrow (BM) cells were 
harvested from femurs and tibias of donor mice. The BM cells were subjected to 
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T cell-depletion using Miltenyi beads.  The adoptive transfer of total BM cells 
was performed 20-24 hours after TBI via tail-vein injection.  For the first two 
weeks after the TBI/BMT transfer, we prevented infections by giving the 
recipient mice drinking water supplemented with 25 mg/L neomycin and 13 
mg/L polymyxin B sulfate (or Baytril).   After week six, blood samples were 
collected from the tails of Bone Marrow Transfer mice for FACS analysis to 
check for hematopoietic cell reconstitution. CD11b/Gr-1 staining was used for 
myeloid cells, CD19/B220 for B cells, and CD3/CD4/CD8 for T cells. In general, 
more than 90% of hematopoietic cells should be derived from the donor, and 
those mice were used for orthotopic injections. 
 
Migration Assay: We performed a migration assay according to a previously 
published method (Zhong et al., 2008). Cells were trypsinized, spun down at 
400G for five minutes, and neutralized with their normal medium containing 
10% FBS. Cells were then washed with PBS, spun down, resuspended in 
serum-free media, counted under the microscope using a hemocytometer and 
trypan blue staining to determine cell viability, and seeded at a density of 5 X 
104 cells per well into the 0.1% Gelatin pre-coated upper chamber of the 24-well 
Transwell migration plates (BD Biosciences).  The upper chamber containing 
cells were placed into the lower chamber containing media with 2% FBS at a 
volume of 600ul/well to act as a chemoattractant.  The cells were allowed to 
migrate through the chamber for 14 hours at 37°C at 5% CO2.  The cells on the 
upper chamber were fixed with 90% ethanol, stained with 0.1% crystal violet 
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blue solution, and rinsed in de-ionized water. The inner portion of the top 
chamber was swabbed to remove all the non-migrated cells.  Migrated cells 
were counted in five microscopic fields at 4x magnification, represented as the 
mean ± standard deviation and subjected to Students t-test for statistical 
significance. 
 
Mouse and Cell Genotyping: Genomic DNA from cells was isolated using the 
Qiagen Genomic DNA Isolation Kit according to the manufacturer’s instructions.  
Genomic DNA was amplified to identify the 393bp band using the following 
chemical master mix: Water, 10X buffer, 10mM Primers (Kras-Forward Primer 
5’ – TCACTGAATTCGGAATATCTTAGAG – 3’; Kras-Reverse Primer 5’ – 
GTTTAAAGCCTTGGAACTAAAGGAC – 3’), 10mM dNTPs, Genomic DNA, and 
Amplitaq (5 units/uL).  Genomic DNA was amplified in an Applied Biosystems 
GeneAmp 9700 PCR Machine with the following program settings for a total of 
35 times: 94°C for 5 minutes, 94°C for 1 minute, 56°C for 1 minute, 72°C for 4 
minutes, and 72°C for 5 minutes with a final hold at 4°C.  Amplified DNA was 
placed on a 2% Agarose-ETBR-stained gel with a molecular weight marker.  
Photos were taken of the agarose gel under UV light. 
 
Primary Fibroblast Isolation: We isolated primary fibroblasts using a 
previously published method (Roybal et al., 2011; Porter et al., 2003). Prior to 
experimentation, sheep anti-rat Dynal-Invitrogen Magnetic Dyna-beads were 
washed and conjugated with single rat anti-mouse antibodies (Cocktail) 
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targeted for different cell-type receptors and left overnight on a rotator at 4°C.  
Primary lung fibroblasts or cancer-associated fibroblasts were isolated from the 
lungs of syngeneic WT 129/SV mice, KrasLA1, and KrasLA1/+; p53R172HDG/+ mice. 
All mice were sacrificed according to the regulations set forth by IACUC and UT 
M.D. Anderson using CO2 and cervical dislocation.  Lungs were briefly perfused 
with 2% FBS-HBSS by intra-tracheal administration and stored on ice.  Lungs 
were dispersed into single cell suspension with 3ug/mL of Collagenase and 
Dispase®II (Roche) and were warmed to 37°C utilizing the gentleMACS™ 
Dissociator from Miltenyi Biotec (Bergisch Gladbach, Germany).  To produce a 
single cell suspension, Miltenyi Biotec programs Lung_01, and Lung_02 were 
used; the cells were centrifuged and washed with 2% FBS-HBSS, and then the 
red blood cells were lysed with RBC Buffer (BioLegend).  Cells were 
centrifuged, washed, and passed through 70µm and 40µm filters to create a 
single cell suspension.  Cells were counted prior to and after every depletion 
using the Invitrogen Countess™.  Cells were placed in an ice bucket on a rocker 
with the pre-washed antibody-conjugated magnetic beads containing the 
following antibody-coated beads: CD45 (Leukocytes), CD31 (enodtelial cells), 
EPCAM (epithelial), and F4/80 (macrophage). After 45 minutes, the solution 
was placed on a magnet for bead/cell isolation (Invitrogen). We collected the 
remaining non-bead conjugated cell suspension and further conjugated it with 
magnetic beads against Thy-1 to isolate the Thy-1Pos cells, which we removed 
from the beads utilizing HBSS-10% containing 0.5% BSA and 2mmol EDTA.  
Cells were washed with HBSS-10%, resuspended, and plated in Alpha-MEM 
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Medium (Cell-Gro) containing 20% FBS, sodium pyruvate (GIBCO), glutamine 
(GIBCO), and 100mg/100 U penicillin-streptomycin (GIBCO). 
 
Primary Fibroblast Matrices: We created Primary Fibroblast Matrices using a 
previously published method (Roybal et al., 2011; Castello-Cros and 
Cukierman, 2009). Three-dimensional ECMs were generated from LF or CAFs 
in cell culture. Cells were plated in 6-well plates precoated with gelatin, 
crosslinked with glutaraldehyde and ethanolamine, washed with PBS, and 
allowed to adhere at 37°C in 5% CO2 conditions.   The ECMs to be analyzed 
grew on cover slips in the 6-well plates.  Cells were supplemented with MEM 
10% FBS and 50ug/mL ascorbic acid and were allowed to grow for 6-8 days to 
generate an intact ECM.  We washed the media with PBS and added Millipore 
ddH2O to lyse the fibroblasts.  ECMs were kept in PBS + Gibco Pen-Strep and 
stored in 4°C in sterile conditions. For analysis of the ECMs, coverslipped 
samples were removed, fixed in Paraformaldehyde, and permeabalized using 
Triton X-100.  Cells were washed with PBS-Tween (PBS-T) and blocked with 
the M.O.M. Vector Shield IgG Blocking kit for mice (Vector Labs).  Samples 
were incubated with primary antibody for one hour at room temperature then 
washed with PBS-T.  Secondary antibody was added and incubated at room 
temperature for 30 minutes.  Samples were washed with PBS-T and then were 
mounted on slides using ProLong Gold Anti-fade with Dapi (Invitrogen).  To 
analyze the samples, we used a confocal microscope (or an epifluoresence 
microscope that can capture along the z-axis).  We acquired images for each 
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color (channel: Krypton/Argon laser with three lines, 488, 568, 647nm for 
excitation of the labels) and repeated the process at least five times on different 
locations of each sample.  
 
Proliferation Assay: We performed a proliferation assay according to a 
previously published method (Roybal et al., 2011). Cells were trypsinized, spun 
down at 400G for five minutes, neutralized with their normal medium containing 
10% FBS, washed with PBS, and placed in serum-free media.  Cells were 
counted under the microscope using a hemocytometer and trypan blue staining 
to determine cell viability.  The cells were placed into media containing 1% FBS 
serum, and the cell density was adjusted to achieve 3 X 104 cells per well in 
100ul of suspension.  The cells were allowed to adhere and were incubated at 
37°C at 5% CO2 for time points every 24 hours for six days.  Cells were washed 
with PBS, trypsinized, and recounted using a hemocytometer to determine cell 
number in eight independent wells per condition.  The results are expressed as 
the mean ± standard deviation and were subjected to Students t-test for 
statistical significance. 
 
Quantitative Real Time PCR: We performed quantitative real time PCR using 
a previously published method (Gibbons et al., 2009a; Roybal et al., 2011; 
Gibbons et al., 2009b). We performed Q-RT-PCR analysis using the ABI 7500 
Fast Real Time PCR Machine (Applied Biosystems), and we normalized the 
results with a comparative method, acknowledging the L32 ribosomal protein 
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mRNA as the endogenous house-keeping gene.  For each reaction, we 
generated a standard curve by using serial dilutions of each of the cDNA.  
SYBR Green I (Applied Biosystems) was used as the fluorophore of detection.  
All experiments were performed in triplicate, and results are expressed as the 
mean ± standard deviation and were subjected to Students t-test for statistical 
significance.  Specific PCR primer sequences for Q-RT-PCR were designed 
with the NIH primer design tool (www.ncbi.nlm.nih.gov/tools/primer-blast/). For 
the complete list of primers please see Table 1.  
 
Subcutaneous Tumor Model: We injected tumors subcutaneously using a 
previously published procedure (Gibbons et al., 2009a; Roybal et al., 2011). 
129/SV mice were injected with tumor cells 1 x 106 (n=10 per cell line) 
subcutaneously in the right flank using RPMI containing 10% fetal bovine serum 
as a vehicle.  After monitoring the mice daily for six weeks, we sacrificed the 
mice and performed necropsies to isolate and weigh the primary tumors and to 
count lung tumor metastases.  The weight of primary tumors and metastases 
are presented as the mean ± standard deviation and were subjected to 
Students t-test for statistical significance. 
 
 
 
 
 
Table	  1:	  	  Primer	  sequences	  used	  in	  RT-­‐PCR	  analysis	  
L32 Forward TGAAGCAGGCATCTGAGGG 
Reverse CGAAGGTGGAAGAG TGGGAG 
E-cadherin  Forward CCGCGGCGCACTACTGAGTT 
Reverse AGGCCGGGCAGGAGTCTAGC 
N-Cadherin Forward TCGAGC ACCCTTCCCCCGAG 
Reverse GCGGTGCGACAAAGCTTCCG 
Vimentin Forward CCAGCACTAGCCGCAGCCTC 
Reverse GGGTCA CATAGGCGCCACCG 
LIFR Forward  CTCTCAGGCCAGAGTTGAGC 
Reverse  GCTGTTCAGTCAGCCCTCTC 
CCR2 Forward TGTCTTCCCTGAATTGAGCC 
Reverse AAACGCATTAGTGGACAGGG 
IL12R Forward CGCAATACGTCGTGCGCTGC 
Reverse CACTCTGACTCCCACGCGCC 
CSF1R Forward GCTGGTGCGGATTCGAGGGG 
Reverse TTCGGCGTTAGTGGCCGAGC 
TGFβR1 Forward ACGCGCTGACATCTATGCAA 
Reverse CGTCGAGCAATTTCCCAGAA 
TGFβR2 Forward GCGCATCGCCAGCACGATCC 
Reverse TGGGCTTCCATTTCCACATCCGA 
CXCR1 Forward TCCTCCTGCCGCTGCTCACT 
Reverse CATGCGCAGTGTGAGCCCGT 
CXCR2 Forward CCTCGTGCCGCTGCTCATCA 
Reverse GGTGCGCAGTGTGAACCCGT 
CXCR3 Forward GGTCGCACTGCTCTGCGTGT 
Reverse GGGGCAGCAGGAAACCAGCC 
CXCR4 Forward GAGGCGTTTGGTGCTCCGGT 
Reverse TCGGTTCCATGGCAACACTCGC 
VEGFR1(Flt1) Forward CGCGTGAAGAGTGGGTCCT 
Reverse CACATGCACGGAGGTGTTG 
VEGFR2(Flk1) Forward AGCCCAGACTGTGTCCCGCA 
Reverse GGTGTCCGCGGAATCGGGTC 
VEGFR3(Flt4) Forward GCCCGAGGACGAGGGTGACT 
Reverse CCTGGCTGCGCCTATCCTGC 
human Flt1  Forward GCACGTCAGCGAAGGCAAGC  
Reverse  CCAGCTCAGCGTGGTCGTAGG  
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Orthotopic Tumor Model: The procedure was followed as previously 
published, with slight modification (Porter et al., 2003).  129/SV mice (n=10 per 
cell line) were swabbed with 70% ethanol on their left side in close proximity to  
the rib cage.  The mice were anesthetized using ketamine/xylazine (40 mg/kg) 
by an intraperitoneal injection. A 20mm incision was made along the left side of 
the mouse, exposing the rib cage. 344SQ cells were injected in a 1:10 dilution 
of Growth Factor Reduced Matrigel (BD Biosceinces) to PBS at a seeding 
density of 2 x 104 cells per 50ml of total suspension per left lobe of the mouse 
lungs. The skin at the surgical site was then closed with surgical staples and the 
mice were allowed to recover from the anesthesia.  The mice were monitored 
daily for three weeks and then were sacrificed, necropsied for tumor burden, 
and examined for visible metastasis.  The weight of both the primary tumors 
and the lungs that showed visible metastasis are presented as the mean ± 
standard deviation and were subjected to Students t-test for statistical 
significance. 
 
3’ UTR Assays: We performed the 3’-UTR assays according to a previously 
published method (Roybal et al., 2011). The 2.0kb Flt1 3’-UTR was isolated 
from a mouse BAC clone by polymerase chain reaction and ligated into the pCI-
neo-hRL vector.  The 1.9kb ZEB1 3’-UTR was subcloned into the same vector 
and was used as a control for these experiments.  The generated reporter 
constructs were cotransfected with the various miR-200 precursors (5 nmol/L, 
Ambion) into 24 well plates containing 1 x105 344SQ cells per well.  Using the 
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Dual Luciferase Reporter Assay (Promega) the luciferase activity was 
measured after 48 hours post-transfection according to the manufacturer’s 
protocol.  We employed a PCR-based site-directed mutagenesis strategy to 
construct the miR-200 binding site mutants using the following primers (the 
mutations are highlighted: (mut1) 5’- 
CCAGCCCCTGACAGGACTATACATCTATGAG-3’ and (mut2) 5’-
GGTTTTATCTCAAGGACTAATATATAGACAA-3’. 
 
Western Immunoblot: We performed a western immunoblot according to a 
previously published method (Roybal et al., 2011; Zhong et al., 2008).  We 
isolated cell lysates with a RIPA buffer and quantified the protein witha Pierces 
BCA Kit.  Protein (35µg) was separated on a SDS-PAGE Gel and transferred 
onto a polyvinylidene fluoride nitrocellulose membrane (Bio-Rad Laboratories).  
Membranes were blocked over night in 5% milk in TBST at 4°C and washed 3X 
for 10 minutes in TBST.  Primary antibodies were added to 2.5% milk in TBST 
and applied to the membrane for overnight incubation at 4°C and then washed 
6X for 5 minutes in TBST.  Secondary antibodies were added to 1% milk in 
TBST, allowed to incubate at room temperature for two hours, and then washed 
3X for 10 minutes. Antibody binding was detected with an enhanced 
chemiluminescence kit according to the manufacturer’s instructions 
(Amersham). 
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Carcinoma-Associated Fibroblasts are biochemically and morphologically 
different from normal lung fibroblasts.  
We must fully understand not only the pathophysiological context of the 
disease but also the molecular and cellular events within the entire 
microenvironment. To further elucidate the stromal contribution to the cancer 
process within the lung tumor microenvironment, we chose to study cancer-
associated fibroblasts (CAF) in metastatic lung cancer disease. While several 
studies of various cancers have shown that CAF promotes angiogenesis, tumor 
cell proliferation, and tumor progression, no other studies, to our knowledge, 
have demonstrated this correlation in metastatic lung cancer (Liao et al., 2009; 
Zhang et al., 2011; Zeine et al., 2009). To that end we used tumor cell lines 
from a murine lung cancer model that develop lung adenocarcinomas with a 
defined metastatic potential through the expression of two specific mutations: 
the first is a common Li-Fraumeni Tp53 mutation (p53R172HΔG/+) found in Li-
Fraumeni patients and the second a KrasLA1/+ (K-rasG12D) mutation (Figure 3A 
and Figure 3B)(Gibbons et al., 2009a; Roybal et al., 2011). Lung tissues from 
K-ras, K-ras p53, and wildtype 129/SV syngeneic mice were enzymatically 
digested with collagenase and dispase into a single cell suspension.  We used 
a magnetic bead approach to acquire CAF from the lungs of mice that express 
a somatic recombination of the latent K-ras (K-rasG12D) mutant allele, CAFp53 
from Kras;p53 mice, and Lung Fibroblasts (LF) from syngeneic 129/SV wildtype 
litermates (Schematically shown in Figure 4)(Johnson et al., 2001). To remove  
 
Experimental Metastasis Model 
lung,	  pancreas,	  adrenal,	  
muscles,	  diaphragm,	  bone	  
13/13	  13/13	  SQ	  	  344	  SQ	  Met	  
0/6	  6/6	  SQ	  393	  LN	  Met	  
0/10	  7/10	  SQ	  	  393	  Primary	  
MetastaCc	  Sites	  Metastasis	  Local	  Route	  of	  InjecCon	  
None	  
None	  
Li-­‐Fraumeni	  mutaCon	  
Lung	  adenocarcinoma	  
(no	  metastases)	  
MetastaCc	  disease	  
A 
B 
Figure 3:  Murine Lung Cancer Models. 
(A)  Schematic representation of the two mouse models (KrasLA1/+ and KrasLA1/+; 
p53R172HΔG/+ mice) used. KrasLA1/+ mice have a spontaneous recombination of the Kras 
G12D allele and develop lung adenocarcinomas that do not metastasize. KrasLA1/+; 
p53R172HΔG/+ have both the Kras and p53 mutation that undergo spontaneous 
recombination to produce metastatic lung adenocarcinomas.  (B) Cell lines isolated from 
KrasLA1/+; p53R172HΔG/+ mice have different metastatic potentials.  Cells were taken from 
various sites of metastases and injected subcutaneously into wildtype 129/SV mice.   Six 
weeks post-injection, mice were sacrificed and metastases were quantified.   These 
results have been previously published (Gibbons 2009).  Figure kindly provided and 
adapted from Don. L Gibbons, M.D., Ph.D. 
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Figure 4:  Primary Cell Isolation Technique. 
Lungs isolated from KrasLA1, Kras;p53, and wildtype129/SV mice littermates were 
mechanically (Mylteni gentleMACS DIssociator Lung Program 1 and 2) and 
enzymatically digested with Collagenase and Dispase to acquire a single-cell 
suspension.  The suspension was then incubated with Dynal magnetic beads that 
had been conjugated to various antibodies that recognize particular cell surface 
receptors for certain cell types.  After 30 minutes of incubation with the beads the 
cell suspension was placed on a magnet to remove the unwanted cells and to 
acquire the cells of interest. 
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all the unwanted cells from the cell suspension, we used a negative selection 
method: antibody-conjugated magnetic beads attracted endothelial cells  
(CD31), leukocytes (CD45 and CD68), macrophage (f4/80), and epithelial cells 
(EP-CAM)(Figure 3). To positively select for fibroblasts, we combined the 
remaining cell suspension with magnetic beads conjugated to Thy1Pos (CD90), 
a glycosylated cell surface protein expressed on lung fibroblasts, thymocytes, 
inflammatory cells, peripheral T cells, and neuronal cells (Rege and Hagood, 
2006). To validate the purity of the cells we performed quantitative real-time 
PCR and western blot analysis on isolated cells, which revealed Thy1Pos 
fibroblasts cells were negative for leukocyte, macrophage, epithelial, and 
endothelial cell surface markers (Figure 5A) and expressed common fibroblast 
markers such as Thy1 and Fibroblast Specific Protein 1(FSP-1)(Figure 5B). 
After culturing, the isolated CAF and LF displayed clear morphological 
differences: CAF were more rounded and smaller with fewer cellular 
projections, whereas LF were more flat and showed heavy branching (Figure 
5C).  In addition to their morphological differences, CAF proliferated more 
rapidly (Figure 5D), expressed higher levels of α-SMA (Figure 5E), and had 
stress fibers arranged in parallel sheets, whereas LF had stress fibers that were 
interwoven (Figure 5F). Cells isolated by the same approach from the lungs of 
KrasLA1/+; p53R172HΔG/+ mice (CAFp53) expressed α-SMA and vimentin and were 
morphologically indistinguishable from CAF derived from KrasLA1 mice (Figure  
5F).  To corroborate our in vitro studies, we performed in situ staining of α-SMA 
on three lung adenocarcinoma patient samples, which revealed positive  
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Figure 5:  Characterization of LF and CAF. 
(A) Primary fibroblasts only express the fibroblast’s marker Thy1. Quantitative RT-PCR 
analysis of LFs. Values normalized on the basis of L32 ribosomal protein mRNA levels. (B)  
Primary fibroblasts express common fibroblast protein markers.   Western blotting of 
fibroblast-specific protein-1 (FSP-1) and Thy-1 (1.1 and 1.2 alleles expressed as two 
distinct bands) in LFs and CAFs. Positive (MLg and NIH3T3) and negative (MEC) controls 
indicated. β-actin used as a loading control. (C) LF and CAF are morphologically different 
from each other.  Morphology of primary lung fibroblasts (light microscopic images at 20x 
magnification). Bar indicates 100 µm.   (D) CAF proliferate faster than LF. LF and CAF 
were seeded at a density of 3.0 X104 and proliferative rate measured with WST-1 Reagent 
after 72 hours.  (E) CAF and CAFp53 exhibit an activated myofibroblast phenotype.  
Detection of fibroblast markers in LFs, CAFs, and CAFp53 by immunocytochemistry 
imaged by fluorescent or light microscopic analysis (20x magnification) of identical fields. 
Bar indicates 200 µm. (F) Distinct patterns of stress fibers in LFs and CAFs.  
Immunofluorescent staining and laser scanning confocal imaging of α-smooth muscle actin 
in 3-D matrices produced by fibroblasts after extraction of cellular debris. Bar indicates 100 
µm.  (G) No evidence of genetic recombination of the latent K-ras allele in CAF. PCR 
amplification of K-ras alleles from genomic DNA use primers that distinguish wild-type 
(bottom arrow) from unrecombined mutant allele (top arrow) on the basis of product size; 
the product generated from the recombined mutant allele is the same size as that of the 
wild-type allele (bottom arrow). Recombination leads to loss of top band. Controls include 
LKR-13 (lung adenocarcinoma cells with recombined KrasLA1 allele) and tail clips from 
wild-type mice (Kras+/+) and KrasLA1/+ mice (heterozygous for KrasLA1 allele).  Adapted and 
reprinted by permission from the American Association for Cancer Research: J.D. Roybal, 
Y. Zang, and Y.-H, et al., miR-200 Inhibits Lung Adenocarcinoma Cell Invasion and 
Metastasis by Targeting Flt1/VEGFR1, Mol Cancer Res, 2010, (9);25, 25-35. 
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staining within the tumors (Figure 6).  Although these features are consistent 
with those of fibroblasts isolated from both tumors and matched normal tissues,  
these differences might be explained by the fact that CAF underwent a somatic 
recombination of the latent K-rasG12D allele, which was excluded by analysis 
of genomic DNA (Figure 5G)(Desmouliere et al., 2004).  
From the above findings we sought to quantify the abundance of Thy1Pos 
fibroblasts within the KrasLA1 mice and the wildtype littermates. The same 
antibody clones used for fibroblast isolation were fluorescently labeled and 
applied to dispersed lung cells for flow cytometric analysis that quantified 
Thy1Pos lung fibroblasts in KrasLA1 mice and wildtype littermates (n=5 for each) 
(Figure 7A) Thy1Pos lung fibroblasts (CD45Neg, CD31Neg, EpCAMNeg, and 
Thy1Pos) constituted a significantly higher proportion of the total dispersed lung 
cell population in KrasLA1 mice than they did in wildtype mice (4.97 ± 0.61% 
versus 3.03 ± 0.28%, respectively, p=0.02, Figure 7B) and were three-fold more 
abundant in KrasLA1 mice than they were in wildtype mice (82,564 ± 22,719 
cells versus 26,748 ± 5,129 cells per lung, respectively, p=0.04, Figure 7C).  
Collectively, these findings from two mouse models of lung adenocarcinoma 
provide evidence of a Thy1Pos CAF population that is morphologically and 
biochemically distinct from its normal tissue counterpart and is more abundant 
in the lungs of tumor-bearing KrasLA1 mice. 
 
 
 
Figure 6: Intratumoral α-SMA expression in human lung 
adenocarcinomas.  
Lung adenocarcinoma patient samples stain positive for the myofibroblast 
marker α-SMA. Lung adenocarcinomas from three patients were stained 
with anti-α-SMA antibodies, which were detected by immunofluorescent 
staining (green). Adjacent tissue sections were stained with hematoxylin 
and eosin.   
B C 
A 
Figure 7: Relative abundance of Thy1Pos LF and CAF in KrasLa1/+ and wild-
type littermates. 
(A) Strategy used for KrasLA1/+ and wildtype littermates. Gating strategy used to quantify 
Thy1pos fibroblasts (Thy1Pos CD45Neg CD31Neg EpCAMNeg) by negative selection of 
hematopoietic cells (CD45Pos), endothelial cells (CD31Pos Sca-1Pos), and epithelial cells 
(Ep-CAMPos) and positive selection of fibroblasts (Thy1Pos). The locations of each cell 
type within flow plots for wildtype mice (left) and KrasLA1 mice (right) are indicated.  
Thy1Pos fibroblasts were quantified based on (B) the relative frequency within the lung 
and (C) the absolute numbers of cells per lung.  
Wildtype KrasLA1 
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Functional interactions between tumor cells and lung fibroblasts. 
 On the basis of the morphological differences between LF and CAF, the 
positive staining of α-SMA on CAF demonstrating an activated fibroblast  
phenotype (Figure 5E), and previous reports of activated fibroblasts having pro-
cancerous effects, we postulated that CAF could promote tumor cell invasion to 
 enhance metastasis. We tested for tumor cell invasion in vitro by co-culturing 
344SQ cells with fibroblasts (LF, CAF, or CAFp53) in a Boyden apparatus, 
which contains two chambers separated by a porous membrane coated with 
Matrigel that allows the exchange of soluble factors between the co-cultured 
cells.  344SQ cells were more invasive in co-culture with CAF or CAFp53 than 
they were in co-culture with LF (2.1-fold, P=0.002, two-sided Student’s t-test, 
Figure 8A).  To further corroborate these results, we conducted studies on four 
other lung adenocarcinoma cell lines derived from KrasLA1/+; p53R172H∆G/+ mice; 
these results showed an increase of invasion of the cancer cells toward CAF 
through the invasion chamber (Figure 8B) and tumor cells reciprocally 
chemoattracted CAF and CAFp53 more prominently than they did LF in the 
dual-chamber migration assays (Figure 9A). We also conducted studies on two 
other lung adenocarcinoma cell lines, which showed an increase in the 
migration of the CAF toward the cancer cells when compared to LF (Figure 9B). 
On the basis of these findings, syngeneic mice were injected subcutaneously 
with a lung adenocarcinoma cell line 393P, derived from KrasLA1/+; 
p53R172H∆G/+ mice (Gibbons et al., 2009b).  Because this cell line has a low 
tumorigenicity, we tested it both alone and in combination with either CAF or LF  
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__ 
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Figure 8: Fibroblast-induced tumor cell invasion. 
(A)  CAF and CAFp53 induce 344SQ invasion.  344SQ cells were mono-cultured (-) 
or co-cultured with LF (LF), CAF, or CAFp53 derived from KrasLA1 mice (CAF) or 
KrasLA1/+; p53R172HΔG/+ mice. Invasive tumor cells were photographed (images) and 
counted in at least 5 separate microscopic fields per well, which were averaged, and 
the mean values per well (± SD) were calculated from replicate wells (bar graphs).  
(B) CAF and CAFp53 induce other tumor cells to invade.  Experiment was repeated 
using other tumor cells (344P, 344LN, 531LN2, and 531LN3) derived from KrasLA1/+; 
p53R172HΔG/+ mice instead of 344SQ.  Adapted and reprinted by permission from the 
American Association for Cancer Research: J.D. Roybal, Y. Zang, and Y.-H, et al., 
miR-200 Inhibits Lung Adenocarcinoma Cell Invasion and Metastasis by Targeting 
Flt1/VEGFR1, Mol Cancer Res, 2010, (9);25, 25-35. 
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Figure 9: Interactions between tumor cells and lung fibroblasts.  
(A) Tumor cell-induced fibroblast migration. Fibroblasts (LF or CAF) were mono-cultured 
(-) or co-cultured with 344SQ cells. Migrated fibroblasts were counted in at least 5 
separate microscopic fields per well, which were averaged, and the mean values per well 
(± SD) were calculated from replicate wells (bar graphs). Images illustrate representative 
fields. (B) Tumor cell-induced fibroblast migration. Fibroblasts (LF or CAF) were mono-
cultured (-) or co-cultured with tumor cells (LKR-13, 344SQ, or 393P). Migration was 
quantified in the same manner as A. (C) Fibroblast-induced tumor growth. 393P tumor 
cells (106 per mouse) were injected alone or co-injected with LFs or CAFs (106 per 
mouse) into subcutaneous flank (n=3 mice per cohort). Resulting tumors were isolated, 
weighed (grams, bar graph), and photographed (image). Tumors that arose in the 
absence of fibroblast co-injection were too small to measure and are not included. 
 37 
to determine whether CAF combined with 393P would increase the 
tumorigenicity and metastatic potential of the 393P cell line(Gibbons et al., 
2009b). Tumors developed in all 10 mice co-injected with CAF or LF (n=5 mice 
for each) and in two of five mice injected with 393P cells alone (P=0.17, Fisher’s 
exact test).  Tumor weight was also significantly greater in mice co-injected with 
CAF than in those co-injected with LF (P=0.001, two-sided Student’s t-test, 
Figure 9C and 9D), which suggests that CAF increase the tumorigenicity of 
tumor cells but do not increase the metastatic potential.  Collectively, these 
findings indicate that lung adenocarcinoma cells have distinct functional 
interactions with LF and CAF. 
 
Proteins secreted by tumor cells and lung fibroblasts.  
Previous reports in the literature and our findings in vitro led us to 
postulate that CAF and LF have disparate secretomes that account for their 
different abilities to induce tumor cell invasion (Mishra et al., 2011). We 
collected conditioned media samples from the dual-chamber Boyden migration 
assays and quantified the concentrations of a panel of cytokines, chemokines, 
and growth factors using BioRad's Luminex Multiplex Magnetic Bead Pro 
technology (Figure 8A, n=9 samples per condition). The Luminex Multiplex 
antibody-based assay revealed at least a two-fold increase in concentration of 
monocyte chemotactic protein-1 (MCP-1/CCL2); the murine functional 
homologues of human CXCL1 (KC and MIP2), VEGF-A, interleukin-6; and 
others when comparing mono-cultures of CAF to either LF or 344SQ (Table 2). 
 Proteins 344SQ LF CAF LF/344SQ CAF/344SQ 
MCP-1 9.11 282.46 2524.16 1182.22*  2711.63*  
MIP-1α  21.29 21.67 59.85 33.2 177.97*  
MIP-1β  0.75 2.71 60.64 14.16*  142.34*  
RANTES 0.5 1.22 19.65 9.40*  29.24 
Eotaxin 76.12 36.8 149.24 86.01 196.3 
KC 486.38 52.69 1191.99 809.42 2370.50*  
MIP-2 2.24 3.9 118.74 31.07*  1119.31*  
MIG 2.51 1.58 31.82 10.08*  69.44*  
bFGF 1.94 2.07 12.57 5.28*  19.08*  
PDGF-β  38.86 22.36 17.41 13.67 13.58 
VEGF-A 61.94 8.3 409.68 85.75*  712.91*  
VEGF-D 0.92 6.33 3.82 0.5 11.75 
IL-1α  0.2 0.33 1.71 0.43 1.56 
IL-1β  6.87 3.36 23.35 10.15*  34.51*  
IL-2 0.75 0.7 1.55 0.69 1.64 
IL-3 0.03 0.18 0.24 0.09 0.29 
IL-4 0.04 1.67 0.21 0.04 0.27 
IL-5  0.41 0.6 1.28 0.49 1.66 
IL-6 1.29 30.2 1838.95 128.90*  675 
IL-9 5.15 2.35 23.67 4.42 24.96 
IL-10 0.87 0.48 2.08 0.85 2.95*  
IL-12(p40) 0.43 0.32 1.65 0.54*  2.21*  
IL-12(p70) 22.89 22.64 39.19 28.82*  41.69*  
IL-13 34.08 27.36 53.69 30.29 61.19 
IL-17 0.23 0.34 0.97 0.25 1.22 
IL-15 2.38 1.78 40.17 12.2*  76.29*  
IL-18 16.02 18.35 55.4 19.44 78.42*  
TGF-β1 852.39 110.68 1875.37 903.56*  2687.85*  
G-CSF 10.09 3.67 47.43 32.76*  122.32*  
GM-CSF 16.37 3.93 12.22 16.21 27.56*  
M-CSF 13.29 32.54 106.95 59.80*  132.21*  
IFN-γ  3.24 2 8.58 3.48 10.85 
TNF-α  7.67 5.82 15.7 8.61 20.92*  
LIF 30.62 7.74 103.94 36.23 171.74*  
Table 2:  Protein concentrations in conditioned media from mono- and co-
cultures. 
Protein concentrations are pg/ml. Comparisons (co-culture versus either of two mono-
cultures) were based on Dunnett's test. * indicates protein concentrations that were 
significantly different (p<0.05) in co-culture relative to that of either of the monocultures. 
Adapted and reprinted by permission from the American Association for Cancer 
Research: J.D. Roybal, Y. Zang, and Y.-H, et al., miR-200 Inhibits Lung Adenocarcinoma 
Cell Invasion and Metastasis by Targeting Flt1/VEGFR1, Mol Cancer Res, 2010, (9);25, 
25-35. 
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Additionally, several proteins increased sharply in the co-cultures relative to 
their levels in mono-cultures, including TGFβ1, VEGF-A, monokine induced by 
interferon-γ (MIG/CXCL9), KC, MIP2, macrophage inflammatory protein (MIP-
1α/CCL3), MIP-1β/CCL4, MCP-1, and leukemia inhibitory factor (LIF, Table 2). 
Moreover, the presence of an activated CAF in the CAF-344SQ co-cultures 
enhanced the secretion of soluble factors in CAF-344SQ co-cultures when 
compared to LF-344SQ co-cultures. Of note, we detected VEGF-A (409.68 
pg/mL) as one of the most abundant proteins in CAF conditioned media 
samples, whereas VEGF-D (3.82 pg/mL), a VEGFR3 ligand, is present at 
extremely low levels. 
Given the high concentrations of ligand proteins in the CAF-344SQ co-
cultures that might regulate 344SQ cell invasion, we chose to narrow the focus 
of our investigation to those ligands for which 344SQ cells expressed receptors 
most prominently. Examination of the mRNA levels of thirteen different 
receptors in 344SQ cells revealed that VEGFR1 (Flt1), VEGFR3 (Flt4), and 
TGFβ type I (Tgfbr1) and type II (Tgfbr2) receptors were over fifty-fold more 
abundant than any of the other receptors expressed on 344SQ (Figure 10A).  
Of note, the high levels of TGFβ receptors are consistent with the reported 
sensitivity of 344SQ cells to TGFβ1-induced EMT and invasion (Gibbons et al., 
2009b). In addition to the mRNA levels, we could readily detect VEGFR1 by 
western blotting of cultured 344SQ cells (Figure 10B) and by 
immunofluorescent staining of 344SQ tumors in syngeneic mice (Figure 10C). 
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Figure 10: Cytokine receptor expression on 344SQ cells.  
(A) Relative mRNA levels of 13 different cytokine receptors in 344SQ cells. 
Quantitative PCR results are the mean values from triplicate samples, which were 
normalized on the basis of Flk1, set at 1.0.  (B) Western blotting of 344SQ cells 
detected VEGFR1 and C-terminal proteolytically cleaved forms of VEGFR3. Murine 
lung endothelial cells (MEC) included as control.  (C) VEGFR1 detected in 
cytoplasmic and plasma membranous compartments. Immunofluorescent staining of 
a 344SQ syngeneic tumor with anti-VEGFR1 antibody (green) and 4',6-diamidino-2-
phenylindole (DAPI, blue) to detect nuclei. Adjacent tissue section stained with 
hematoxylin and eosin. . Adapted and reprinted by permission from the American 
Association for Cancer Research: J.D. Roybal, Y. Zang, and Y.-H, et al., miR-200 
Inhibits Lung Adenocarcinoma Cell Invasion and Metastasis by Targeting Flt1/
VEGFR1, Mol Cancer Res, 2010, (9);25, 25-35.  
A B 
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VEGFR1 promotes tumor growth, invasion, and metastasis.  
To model the effects of VEGFR1 targeting on tumor cells, we stably 
introduced VEGFR1 short hairpin RNA (shRNA) into 344SQ cells.  We chose 
two 344SQ_VEGFR1 shRNA clones (#2-3 and #4-1) that expressed decreased  
VEGFR1 mRNA and protein levels for further study (Figure 11A).  The 
VEGFR1-depleted tumor cells demonstrated a decrease in proliferation in 
monolayer culture (Figure 11B), a decrease in invasion in co-culture with CAF 
(Figure 11C), and a decrease in colony formation in soft agar (Figure 11D).  
Additionally, when we subcutaneously injected the VEGFR- depleted cells into 
syngeneic mice, we saw a decrease in the metastatic potential of these cells 
when compared to the scramble control shRNA transfectants (Figure 11E). 
Because VEGFR1 is required for tumor growth and metastasis, we 
posited that VEGFR1 expression in primary tumors adversely affects the clinical 
outcome for lung adenocarcinoma patients.  We mined publicly available gene 
expression databases for VEGFR1 mRNA expression in resected tumors from 
two cohorts of early-stage lung adenocarcinoma patients that are well-
annotated for clinical outcome (Chitale et al., 2009; Tomida et al., 2009). We 
grouped and compared the patients on the basis of VEGFR1 expression (top 
quartile versus the lower three quartiles) and the duration of survival in the two 
groups (Figure 12A). We observed that patients in the top quartile of one cohort 
fared worse, having a significantly shorter duration of survival than did those in 
the lower three quartiles (P=0.007, Log-rank test; P=0.016, univariate Cox, 
Figure 12A)(Tomida et al., 2009).   We discovered a similar correlation between  
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Figure 11: Biologic properties of tumor cells regulated by VEGFR1.  
(A) Suppression of VEGFR1 by VEGFR1 shRNA. Quantification of VEGFR1 in two 
independent clones of 344SQ  transfected with VEGFR1 shRNA (#2-3, #4-1) or scrambled 
shRNA (SCR) by quantitative RT-PCR of triplicate RNA samples (bar graph) and western 
analysis of protein (gels); bands were quantified densitometrically. VEGFR1 RNA and 
protein levels were normalized on the basis of L32 ribosomal protein mRNA and actin 
levels, respectively, and expressed relative to controls, which were set at 1.0.  (B) VEGFR1 
knockdown inhibits 344SQ proliferation. Transfectants were seeded in monolayer cultures, 
counted, and expressed as mean values (± S.D.) of quadruplicate samples.  (C) VEGFR1 
knockdown inhibits CAF-induced tumor cell invasion. Transfectants were co-cultured with 
CAF; invasive tumor cells were photographed (images) and counted in 5 separate 
microscopic fields per well, averaged, and mean values per well (± S.D.) were calculated 
from replicate wells (bar graphs).  (D) VEGFR1 knockdown inhibits 344SQ anchorage-
independent growth. Transfectants were seeded in soft agar, and visible colonies were 
photographed (images) and counted (bar graph) at 21 days. Results expressed as mean 
values (± S.D.) of triplicate samples.  (E) VEGFR1 knockdown inhibits tumor metastasis. 
Syngeneic mice were injected subcutaneously with tumor cells and necropsied at 6 weeks 
to measure primary tumor size and count lung metastases (scatter plots). Mean values are 
represented by long horizontal lines; standard deviations are represented by short 
horizontal lines.  Adapted and reprinted by permission from the American Association for 
Cancer Research: J.D. Roybal, Y. Zang, and Y.-H, et al., miR-200 Inhibits Lung 
Adenocarcinoma Cell Invasion and Metastasis by Targeting Flt1/VEGFR1, Mol Cancer Res, 
2010, (9);25, 25-35. 
A 
Figure 12. Correlation of VEGFR1 expression with duration of survival and 
schematic illustration of findings from this study.  
(A) High VEGR1 expression correlates with a decrease in overall survival and free-relapse 
survival.  Kaplan-Meier analysis of two cohorts of lung adenocarcinoma patients on the basis 
of VEGFR1 expression (top quartile versus lower three quartiles) in resected primary tumor 
specimens. (B) Avastin treatment suppressed migration in co-cultures.  Fibroblasts (LF or 
CAF) were mono-cultured (-) or co-cultured with 344SQ cells and 5 µg/mL of Avastin or IgG. 
Migrated fibroblasts were counted in at least 5 separate microscopic fields per well, which 
were averaged, and the mean values per well (± SD) were calculated from replicate wells 
(bar graphs). Images illustrate representative fields.  (C) Avastin treatment decreases 
proliferative rates in mono- and co-cultures.  344SQ cells were seeded at a density of 3.0 
X104 (n=6 wells per plate); mono- or co-culture conditioned medium plus 5 µg/mL of Avastin 
or IgG was added to the wells.   The proliferative rate was measured with WST-1 reagent 
after 72 hours.  (D)  Avastin neutralized tumor cell invasion in mono- and co-cultures. 344SQ 
cells were mono-cultured (-) or co-cultured with LF (LF) or CAF and 5 µg/mL of Avastin or 
IgG. Invasive tumor cells were photographed (images) and counted in at least 5 separate 
microscopic fields per well, which were averaged, and the mean values per well (± SD) were 
calculated from replicate wells (bar graphs). (E and F) Tumor cell invasion induced by 
recombinant VEGF-A. The indicated tumor cell lines derived from KrasLA1/+; p53R172HΔG/+ mice 
were mono-cultured in the upper chamber of a dual-chamber well, and recombinant VEGF-A 
was added (+) or not added (-) to the lower chamber. Invasive tumor cells were 
photographed (images) and  quantified(bar graphs) the same way as (B).  Adapted and 
reprinted by permission from the American Association for Cancer Research: J.D. Roybal, Y. 
Zang, and Y.-H, et al., miR-200 Inhibits Lung Adenocarcinoma Cell Invasion and Metastasis 
by Targeting Flt1/VEGFR1, Mol Cancer Res, 2010, (9);25, 25-35.  
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VEGFR1 expression and relapse-free survival in a second cohort (n=193, 
P=0.01, Log-rank test; P=0.08, univariate Cox, Figure 12A), indicating that 
VEGFR1 expression may adversely impact the clinical outcome for certain lung 
adenocarcinoma patient cohorts (Chitale et al., 2009).  To further demonstrate  
that neutralization of VEGFR1 on tumor cells could be beneficial as a lung 
cancer treatment, we treated in vitro co-cultures with 5µg/mL Bevacizumab, 
also known as Avastin. Bevacizumab is a humanized monoclonal antibody 
commonly used in the clinic to reduce tumorigenesis in lung adenocarcinoma 
patients; the antibody binds onto VEGF-A to neutralize the protein and prevent 
VEGF-A from binding onto its receptor in order to reduce angiogenesis 
(Yancopoulos, 2010).  We used the monoclonal antibody in the co-culture 
assay and saw a decrease in the migration of CAF and LF toward 344SQ 
(Figure 12B) and a reduction in 344SQ cell proliferation in monolayer cultures 
(Figure 12C). Corresponding to the migration assays, we performed in vitro 
invasion assays with 344SQ cells and CAF or LF with the summation of 
Bevacizumab treatment, which demonstrated a reduction in the invasiveness of 
344SQ in response to the presence of CAF or LF (Figure 12D).  Given the high 
levels of VEGF-A relative to that of VEGF-D (712.9 versus 11.7 pg/ml, Table 1), 
we added recombinant VEGF-A as a chemoattractant to the lower chamber of 
in vitro invasion assays, which enhanced the invasion of four of the five lung 
adenocarcinoma cell lines examined (Figure 12E).  In contrast to our data, 
which showed that the recombinant peptide is capable of acting as a 
chemoattractant, applying a VEGF-A neutralizing antibody in in vitro co-culture 
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assays demonstrated a decrease in the migratory potential of fibroblasts toward 
tumor cells (Figure 13A) and a decrease of invasiveness of the tumor cells 
toward CAF or LF (Figure 13B and 13C).   All these findings indicate that the 
stimulation of VEGFR1 by VEGF-A is a key signaling pathway within our murine 
model of metastatic lung cancer. 
 
VEGFR1 is a miR-200 target gene.  
Given our results and previous reports that miR-200 is a master regulator 
of EMT and metastasis within this model, we posited that VEGFR1 is a miR-200 
target gene (Gibbons et al., 2009b). We tested this hypothesis by co-culturing 
CAF with 344SQ cells that were stably transfected with lentiviral vectors 
expressing miR-200b/a/429 (344SQ_200b) or nothing (344SQ_vec). Forced 
expression of miR-200b in 344SQ cells decreased CAF-induced tumor cell 
invasion by 66% (P=0.001, two-sided Student’s t-test, Figure 14A) and 
decreased VEGFR1 mRNA and protein levels by 73% and 38%, respectively, 
whereas the mRNA levels of other cytokine receptors did not change Figure 
14B).  To further validate this hypothesis and the above findings, we examined 
whether or not miR-200 decreased VEGFR1 levels by targeting sequences in 
the Flt1 3’-untranslated region (3’-UTR).  Analysis using the target scan tool 
(www.targetscan.org) revealed two putative miR-200b/c/429 binding sites in the 
Flt1 3’-UTR (diagrammatically illustrated in Figure 14C).  One is located from 
nucleotides 33 to 39 and has similar scores for the bona fide miR-200b/c/429 
binding sites within the Zeb1 3’-UTR with the probability of conserved targeting  
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Figure 13: Anti-VEGFR1 reduces tumor cell invasion. 
(A) Tumor cell-induced fibroblast migration was reduced by anti-VEGF-A treatment.  Anti-
VEGF-A or IgG was added (+) or not added (-) to the lower chamber containing 344SQ 
cells of co-cultures. LF or CAF were photographed (images) and counted in at least 5 
separate microscopic fields per well, which were averaged, and the mean values per well 
(± SD) were calculated from replicate wells (bar graphs).  (B and C) Tumor cell invasion 
induced by recombinant VEGF-A.   The indicated tumor cell lines derived from KrasLA1/+; 
p53R172HΔG/+ mice were mono-cultured in the upper chamber of a dual-chamber well, and 
anti-VEGF-A or IgG was added (+) or not added (-) to the lower chamber. Invasive tumor 
cells were photographed (images) and counted in at least 5 separate microscopic fields 
per well, which were averaged, and the mean values per well (± SD) were calculated 
from replicate wells (bar graphs).  Adapted and reprinted by permission from the 
American Association for Cancer Research: J.D. Roybal, Y. Zang, and Y.-H, et al., 
miR-200 Inhibits Lung Adenocarcinoma Cell Invasion and Metastasis by Targeting Flt1/
VEGFR1, Mol Cancer Res, 2010, (9);25, 25-35.  
344SQ + CAF  344SQ + CAF  
344SQ + CAF  344SQ + LF  
_ + α-VEGF 
CAF + 344SQ  
LF + 344SQ  
+ α-VEGF + IgG 
Control	   200b	  
0
500 
1000 
1500 
2000 P=0.001 
in
va
de
d 
ce
lls
 n
um
be
r 
(5
 fi
el
ds
) 
Tg
fb
r1
 
0.0 
0.5 
1.0 
1.5 
0.0 
0.5 
1.0 
1.5 P<0.0001 
Ve
gf
r1
 
C
xc
r2
 
0.0 
0.5 
1.0 
1.5 
C
cr
2 
0.0 
0.5 
1.0 
1.5 
2.0 
B 
VEGFR1 
Actin 
   1       0.62  
C 
x 
x 
Figure 14:  Flt1 is a miR-200 target gene.  
(A) miR-200 suppresses CAF-induced tumor cell invasion. Transwell invasion assays of 
344SQ cells that stably express miR-200b (200b) or empty (control) lentiviral vectors in co-
culture with CAF. Invaded cells were stained, photographed (image), and counted in at 
least 5 separate microscopic fields per well, which were averaged, and the mean values 
per well (± S.D.) were calculated from replicate wells (bar graph).  (B) miR-200 suppresses 
VEGFR1 expression. Quantitative RT-PCR analysis (bar graphs) of 344SQ cells stably 
transfected with miR-200 (200b) or empty (control) lentiviral vectors normalized on the 
basis of L32 ribosomal protein mRNA levels and expressed as mean values of triplicate 
cultures relative to control transfectants, which were set at 1.0. Western blotting (gels) of 
the same transfectants. Actin included as loading control. VEGFR1 bands were quantified 
densitometrically, normalized on the basis of actin, and expressed relative to control, set at 
1.0.  (C) miR-200 targets sequences in the Flt-1 gene 3’-UTR. Reporter constructs 
containing wild-type and mutant Flt1 3’UTR are illustrated diagrammatically (top). 344SQ 
cells were transiently co-transfected with pre-miRs (10 nM) and reporter plasmids (500 ng) 
that express luciferase alone (con) or are linked to the full-length 3’-UTR of Zeb1 (Zeb1) or 
Flt1 that is wild-type (Flt1) or mutated at the 5’ (mut1) or 3’ (mut2) putative miR-200 binding 
site. Results were normalized on the basis of renilla luciferase and expressed as the mean 
values of triplicate wells (* p<0.05).   Adapted and reprinted by permission from the 
American Association for Cancer Research: J.D. Roybal, Y. Zang, and Y.-H, et al., miR-200 
Inhibits Lung Adenocarcinoma Cell Invasion and Metastasis by Targeting Flt1/VEGFR1, 
Mol Cancer Res, 2010, (9);25, 25-35. 
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score or PCT score (Friedman et al., 2009) of 0.84, and the other is located from 
nucleotides 847 to 853 and has a PCT score < 0.10. In contrast, no putative 
miR-200 binding sites with PCT scores > 0.80 were found within the 3’-UTR of 
genes encoding CCR1, CCR2, CCR5, CXCR2, CXCR3, type I and II TGFβ 
receptors, IL6Rα, IL18R1, or c-Fms.   In addition to testing a negative control in  
344SQ cells, we created a positive reporter plasmid containing a luciferase 
fused to 3’-UTR sequences from Flt1 and Zeb1 and generated our hypothesis-
testing cells by transiently co-transfecting 344SQ cells with synthetic miR-200 
precursors (200a, 200b, 200c, 141, or 429)(Figure 14C). After comparing miR-
200b and miR-200c to scrambled control oligomers (negative control luciferase 
reporter), we observed a decrease of 50-60% in the luciferase activity of the 
FLT1 3’-UTR, which was similar to the Zeb1 3’-UTR reporter (positive 
control)(Figure 14C). The site-directed mutagenesis of the 5’ putative miR-200 
binding site negated this suppression of luciferase activity, but the 3’ binding 
site had no effect (Figure 14C).  We demonstrated that the regulation of 
VEGFR1 is specific to miR-200b and miR-200c, because miR-200a and miR-
429 (other miR-200 family members) did not have an effect on the FLT1 3’-UTR 
luciferase reporter activity (Data not shown). 
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Comparative studies on CAF and normal tissue counterparts from a 
variety of epithelial organs have revealed striking functional and phenotypic 
differences, including opposing roles in tumorigenesis (Begley et al., 2008; 
Bhowmick et al., 2004a; Bhowmick et al., 2004b; Trimboli et al., 2009).  These 
data indicate that tumors contain heterogeneous fibroblast populations with 
diverse and even conflicting effects on tumor cells. We explored the 
quantitative, phenotypic, and functional differences between normal and 
cancer-associated lung fibroblasts in mouse models of lung adenocarcinoma 
and found differences with respect to abundance, myofibroblast features, rates 
of proliferation, diversity and abundance of secreted proteins, and interactions 
with tumor cells. Although when comparing the individual cells within the 
population of cells, the CAF and LF populations appear to be homogeneous on 
the basis of morphology and marker expression, these findings do not exclude 
the possibility of biologically or phenotypically distinct fibroblast subpopulations 
within the larger Thy1Pos fibroblast pool.  The phenotypic and functional diversity 
of normal lung fibroblasts, which have been subdivided on the basis of their 
expression of Thy1, cyclooxygenase-2, and telomerase, supports this possibility 
(Hardie et al., 2009). Although this presents a complicated picture with respect 
to the potential role of lung fibroblasts in the development of lung malignancy, 
our findings clearly demonstrate that a Thy1Pos-specific CAF population 
promotes tumor growth and invasion. These cells share phenotypic and 
functional features with a Thy1Pos CAF population reported in human lung 
cancers (Nazareth et al., 2007). Although their origin is uncertain, the CAF 
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reported here may arise from lung fibroblasts or other Thy1Pos cells originating 
from the bone marrow, such as CD45Pos Col1Pos CXCR4Pos fibrocytes that traffic 
to wounded areas of the lung in response to injury (Craig et al., 1993; Phillips et 
al., 2004).  
A growing body of evidence demonstrates that CAF recruit macrophages 
and endothelial cells and thereby regulate tumor inflammation and 
angiogenesis (Erez et al.; Nazareth et al., 2007). Similarly, findings from 
conditioned medium samples revealed that CAF secrete a plethora of 
cytokines, chemokines, and growth factors that can recruit endothelial cells 
(VEGF-A, KC, and MIP-2) or regulate inflammatory cell recruitment and function 
(MCP-1, MIP1α, MIP-1β, KC, MIP-2, M-CSF, TGFβ1, and interleukin-6). 
Furthermore, we examined direct interactions between tumor cells and CAF by 
establishing in vitro co-culture models and in vivo co-injection models and found 
that CAF potently induced tumor cell invasion and enhanced tumor growth in 
mice. Cytokines secreted by CAF that could have mediated these effects 
include TGFβ1, which induces tumor cells from these mice to undergo EMT 
(Gibbons et al., 2009b), and VEGF-A, which was sufficient to chemoattract 
tumor cells in invasion assays and was required for CAF-induced tumor cell 
invasion (Figure 15). Findings from VEGFR1 knockdown experiments support 
the conclusion that VEGF-A promotes tumor cell proliferation and invasion in 
vitro and tumor growth and metastasis in mice. Collectively, these findings 
demonstrate that CAF secrete multiple cytokines that induce tumor cells to 
undergo diverse biologic processes that promote tumorigenesis, illustrated  
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Figure 15:  Model that summarizes our findings. 
Schematic illustration shows CAF-derived cytokines binding directly to receptors on 
tumor cells and inducing tumor cells to suppress miR-200 levels, to undergo EMT 
(TGF-beta), and to invade (VEGF-A). 
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schematically in Figure 15.  After identifying functional interactions between 
tumor cells and CAF that drive tumor progression, we tested the hypothesis that 
miR-200 targets receptors on tumor cells that transmit paracrine signals from 
CAF. The findings presented here support the conclusion that miR-200 
regulates tumor cell sensitivity to VEGF-A by directly targeting VEGFR1 (Figure 
15). Given that miR-200 had heretofore been recognized solely for its capacity 
to regulate EMT in a cell-autonomous manner, our results demonstrate a multi-
functional role for miR-200 and further support a current paradigm that suggests 
that tumor cells acquire multiple biologic properties by targeting a single miR 
(Gregory et al., 2008; Park et al., 2008). The bona fide miR-200 target genes 
reported thus far include ZEB1 and ZEB2, which transcriptionally regulate EMT 
markers, tight junctional elements, various polarity genes, and USH/FOG2, an 
inhibitor of the p85 regulatory subunit of phosphotidylinositol 3-kinase (Gibbons 
et al., 2009b; Bracken et al., 2008; Burk et al., 2008; Hyun et al., 2009). The 
complexity of the miR-200 transcriptome in this model, which encompasses 
over 3,000 genes that encode proteins with diverse intracellular functions, 
warrants further studies to discover other miR-200 target genes that regulate 
tumorigenesis (Gibbons et al., 2009b). The finding that VEGFR1 was not 
sufficient to restore metastasis in tumor cells that constitutively express miR-
200 supports the multiplicity of those miR-200 target genes.  On a speculative 
note, undiscovered miR-200 target genes might include chemokines and 
cytokines secreted by tumor cells that chemoattract CAF and other cell types to 
the microenvironment would create a negative feedback loop in which miR-200 
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interrupts the cell-cell interactions that induce tumor cells to undergo EMT and 
metastasize.   
VEGF-A neutralizing antibodies have been proven efficacious as single 
agents in patients with renal cell carcinomas because they inactivate VHL gene 
mutations that constitutively activate hypoxia-inducible factorα and drive VEGF 
expression; these antibodies have also been effective in combination with 
chemotherapeutic agents in patients with VHL-wild-type tumors, such as non-
small cell lung cancer and colon cancer (Bose et al., 2010). The therapeutic 
efficacy of VEGF antagonists has been attributed primarily to a suppression of 
tumor angiogenesis by reducing the chemoattraction of endothelial cells, 
pericytes, and hematopoietic precursors that express VEGFR1. A growing body 
of evidence in other models demonstrates that VEGF-A directly promotes tumor 
cell invasion, and our findings suggest that these agents may have the 
additional therapeutic benefit of decreasing tumor cell sensitivity to VEGF-A 
(Wey et al., 2005; Lichtenberger et al.; Naik et al., 2009). 
 
 
 
 
 
 
 
 
 55 
 
 
Chapter Five 
Future Directions 
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The cell of origin.  
Our findings clearly indicate that Thy1Pos fibroblasts are important cells 
within the tumor microenvironment because they can signal the tumor cell 
through cytokine, chemokine, and growth factor networks to aid in processes 
that govern metastases. CAF have multiple cells-of-origin, including resident 
fibroblasts, endothelial cells, adipocytes, and bone marrow-derived 
mesenchymal cells (Wu and Zhou, 2009; Wipff et al., 2007; Hinz, 2007; Hinz et 
al., 2007).   To our knowledge the origin of the Thy1Pos lung fibroblast has not 
been fully elucidated in normal and cancerous lungs of mice. Many cell types 
express Thy1 as a cell-surface marker, and because leukocytes and T-cells 
express Thy1, we hypothesized that resident Thy1Pos lung fibroblasts were 
derived from the bone marrow. We addressed this question by lethally 
irradiating wildtype 129/SV mice to remove their native bone marrow; after 
grafting the mice with constitutive YFP bone marrow (BM-YFPPos) from B6.Cg-
Tg(EYFP)AGfng/J mice, at greater than 80% engraftment (Figure 17A),  we 
orthotopically injected these mice with 2.0 X104 344SQ cells for three weeks 
(shown in Figure 16).  344SQ cells were used as a chemoattractant to draw the 
BM-YFPPos cells to the lungs.  We performed FACS analysis to isolate and 
analyze the cells using a gating strategy that separated first the hematopoietic 
cells from large granular cells and then subgated those cells that were double 
positive for Thy1 and YFP and CD45Neg.  The results showed that a greater 
proportion of these Thy1PosYFPPosCD45Neg cells were mostly small in  
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Figure 16:  Bone Marrow-derived fibroblast experimental design. 
(1-3)129/SV mice were lethally irradiated and engrafted with bone marrow from B6.Cg-Tg
(EYFP)AGfng/J mice that express constitutive expression of YFP.  (4)  The mice that had 
greater than 80% reconstitution of the YFP bone marrow were subjected to orthotopic 
injection of 344SQ cells (2.0 X 104 cells) or none at all.  (5)  The mice were sacrificed 
three weeks post-surgical operation.  Total mice were n=10 for injected and n=10 for non-
injected mice.   
Bone	  Marrow	  Experimental	  
Design	  
A 
Figure 17:  Bone-Marrow Derived CAF studies. 
(A) Lethally irradiated with YFP engrafted bone marrow cells demonstrated greater than or 
equal to eighty percent reconstitution.   Peripheral blood was taken from the tails of 
reconstituted mice and subject to flow cytometry analysis for YFP positive cells.  Results are 
shown with the results of six mice. (B and C) The bulk of the cells, greater than ninety-one 
percent of YFP+ cells, are hematopoietic as demonstrated by the broad hematopoietic 
marker CD45.   Mice were sacrificed 3 weeks post orthotopic injection or non-injection of 
344SQ cells into the lungs.  Cells enzymatically digested into a single-cell suspension and 
subjected to FACs analysis for YFPPosThy1PosCD45Neg cells.  (D) There are more 
YFPPosThy1Pos cells in non-injected mice than in injected mice.  Quantification were 
expressed as a percent between the two groups. (E) YFPPosThy1PosCD45Neg cells are a rare 
population in these mice.  Totals were expressed as percentages from total quantification. 
B 
C D 
E 
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size (Figure 17) and likely to be hematopoietic cells (Figures 17B and 17C). 
Moreover, there was an increase in double positive Thy1Pos- YFPPos cells in the 
non-injected mice when compared to those mice that had been orthotopically 
injected (Figure 17D). The data demonstrate that these cells are a rare 
population in these mice, in comparison to the overall percentage of cells in the 
lungs (Figure 17E). Unfortunately, all the cells in the bone marrow of these mice 
constitutively express YFP, and YFP is not driven by a promoter that is specific 
for Thy1 or for bone marrow cells; this allows for background when collecting 
the cells and analyzing the data from those results. A more elegant experiment 
would use the bone marrow from mice that express YFP under the control of 
the Thy1 promoter, which would definitely identify whether the tumor cells were 
able to chemoattract the Thy1Pos bone marrow cells. Additionally, colocalization 
studies with YFP and different colored markers for fibroblasts, such as FSP-1 
and α-SMA, would definitively identify whether or not the fibroblast cells were 
bone marrow-derived.  However, taken together these data suggest that only a 
very small percentage of the Thy1Pos fibroblasts could be BM-derived (Figure 
17E), which leads us to speculate further that these cells could be precursor 
fibroblasts that are changed into CAF in the tumor microenvironment. 
Others have also shown that CAF are derived from precursor fibroblasts 
that are resident in the normal tissue and become CAF upon tumorigenesis 
formation(Wu and Zhou, 2009; Wipff et al., 2007; Hinz, 2007; Hinz et al., 2007; 
Grivennikov et al., 2010). More specifically, recent studies have demonstrated 
that certain secreted soluble factors are capable of re-educating fibroblasts to a 
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CAF phenotype by taking conditioned media from cancer cells and placing it on 
normal fibroblasts to elicit the change to a CAF (Erez et al., 2010). The current 
published data and our recent findings in the bone marrow experiments lead us 
to speculate that LF have been re-educated within the tumor microenvironment 
to become CAF. As previously demonstrated by other groups, a series of 
similar experiments could be performed to identify whether or not this is the 
case by adding CAF conditioned medium or 344SQ conditioned medium to LF 
cultures and using our in vitro migration and invasion experiments as a readout.  
Additionally, immunofluorescence staining for increased expression of α-SMA 
and Vimentin expression would identify whether or not these cells become 
activated to a myofibroblast state.  Taken together, all these data would further 
validate the hypothesis that the soluble secreted factors within a particular 
microenvironment could elicit a fibroblast to become a pro-cancerous fibroblast. 
 
Three-dimensional cultures.  
Current research has focused on the type of assays that comprise the 
microenvironment in which we culture our cells and run our assays. It is 
becoming more recognized that the cells respond differently in three-
dimensional assay compared to a two-dimensional type system (Gibbons et al., 
2009b; Grimshaw et al., 2008). To test this aspect we used a previously 
published three-dimensional assay, an in vitro sphere assay in which 344SQ 
cells are placed on growth factor reduced Matrigel in normal culturing conditions 
(Gibbons et al., 2009b).  When the cells are in those conditions, 344SQ express 
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typical polarity markers and form a hollow sphere with distinct morphology and 
grow to about 100µm in size (Gibbons et al., 2009b). To identify whether or not 
LF or CAF had a morphological effect on 344SQ cells in three-dimensional 
cultures, we co-cultured 344SQ cells with LF ad CAF in the sphere assay 
(Gibbons et al., 2009b). Co-culturing CAF with 344SQ spheres demonstrated a 
change in the spheres’ morphology from round hollow spheres to non-round 
spheres with irregular elongated projections (Figure 18A); when LF was co-
cultured with 344SQ, the spheres' morphology did not change (Figure 18A). 
These results from the three-dimensional assays suggest that these CAF are 
contributing to the pro-cancerous phenotype either through direct cell-cell 
contacts or by some other mechanism, such as their extracellular matrix 
environment. 
 
CAF secrete a pro-cancerous extracellular matrix.  
The soluble secreted factors are important not only within the tumor 
microenvironment but also in the native niche that encompasses the tumor, 
such as the extracellular matrix.  It is well-known and accepted that fibroblasts 
secrete extracellular matrix molecules (collagen, elastin, and fibronectin, etc) 
that provide the structural integrity of the basal lamina in the normal pathology 
of the tissues.  On that note it has also been documented that CAF can secrete 
extracellular matrices that are pro-tumorigenic in breast cancer models  
 
 
34
4S
Q
-G
FP
 
__ + LFs + CAFs 
Figure 18: CAF and CAF-derived matrix causes morphological 
changes in 344SQ spheres. 
A) Fibroblast-induced tumor sphere morphology changes. GFP-tagged 344SQ 
spheres in mono-culture (-) or co-culture with fibroblasts (LF, CAF). Coordinate 
fields visualized by light (top) or immunofluorescence (bottom) confocal 
microscopy (40x). Bar indicates 200 µm.  (B) CAF matrix-induced tumor sphere 
morphology changes. GFP-tagged 344SQ spheres in mono-culture (-) or co-
culture with matrix derived from CAF. Coordinate fields visualized by light (top) or 
immunofluorescence (bottom) confocal microscopy (40x). Bar indicates 200 µm. 
344SQ-GFP 
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(Castello-Cros et al., 2009).  A previously published method allowed us to 
isolate the extracellular matrix from both LF and CAF (Castello-Cros and 
Cukierman, 2009). When we placed the CAF matrix on top of 344SQ spheres in 
the sphere assay, the matrix induced a morphological change in the spheres 
(Figure 18B). Because the matrix had to be in direct contact with the sphere in 
order to cause a morphological change (clearly demonstrated in Figure 18B), 
we speculate that the extracellular matrix laid down by CAF is also critically 
important to the cancerous phenotype. Future studies are needed to identify the 
differences between the LF and CAF matrices to identify the potential 
molecules that can regulate the morphological change within these three-
dimensional assays. These findings elicit an exciting new branch of studies 
within the metastatic tumor microenvironment. 
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would create a genetically modified and enhanced source of food and nutrients 
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